(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
The deal gives Cabaletta a non-exclusive licence for LentiVector to be used on Chimeric autoantibody receptor T programme, DSG3-CAART, for autoimmune disease.
No financial details were revealed, but Oxford Biomendica said the arrangements of the LSA were "in line with comparable deals the group has previously secured".
Oxford Biomedica (OXB)9 May 2024 11:02
CORRECT: Avon Protection wins UK MoD supply deal; Molten Ventures up
(Correcting headline)